Methylene Blue and G6PD Deficiency: The Screen Before the Script
There is a blood test that should precede every first prescription of methylene blue, and most people who buy it online have never had it. It costs little, it is drawn with the baseline panel, and the thing it rules out is a person's red blood cells breaking apart in their bloodstream.
This page explains what G6PD deficiency is, why it matters specifically for methylene blue, and why "I've never had a problem" is not evidence of anything.
What G6PD does
Glucose-6-phosphate dehydrogenase is an enzyme inside red blood cells. Its job is to keep the cell's supply of a protective molecule, reduced glutathione, topped up. Red cells have no nucleus and no way to repair themselves; that glutathione buffer is most of what stands between them and oxidative damage from the drugs, infections and foods they encounter.
A person with a G6PD variant has less of the enzyme, or a less stable version of it. Their red cells manage fine under ordinary conditions and fail under oxidative stress — the cell membrane gives way and the cell breaks open, releasing hemoglobin into the plasma. Enough cells break at once and the result is hemolytic anemia: fatigue, breathlessness, yellowed skin and eyes, dark urine, and in severe cases kidney injury or the need for transfusion.
G6PD deficiency is the most common enzyme deficiency in humans. It affects something in the region of 400 million people, is carried on the X chromosome — so men are more often and more severely affected — and is most frequent in people with ancestry from Africa, the Mediterranean, the Middle East and South and Southeast Asia. Most carriers are unaware, because nothing has yet stressed their red cells hard enough to show it.
Why methylene blue in particular
Methylene blue is an oxidizing agent — that is part of how it works, and in most people it is unremarkable. In a red cell that lacks G6PD, it is exactly the stress the cell cannot buffer. Hemolysis with methylene blue in G6PD-deficient people is well documented, including deaths, and it is listed as a contraindication on the label of every approved methylene blue product.
There is a further irony. Methylene blue is the standard treatment for methemoglobinemia — a condition in which hemoglobin cannot carry oxygen — and in a G6PD-deficient patient it not only fails to treat that condition but can make it worse, because the pathway methylene blue relies on to work is the same one G6PD supports. That failure is how the interaction was first recognized in hospitals.
For a person taking methylene blue for energy or cognition, the stakes are simpler: it is an avoidable cause of a serious anemia, and it is avoided by a blood test.
What we do
We test before the first prescription, without exception. A quantitative G6PD enzyme assay, drawn with the baseline panel. The result is on file before methylene blue is considered.
A deficient result is a contraindication, not a caution. There is no version of methylene blue that is appropriate in a person with G6PD deficiency, and we will say so and move on to whatever else might serve the goal.
A normal result in a woman is read carefully. Because the gene is on the X chromosome, a woman can carry one deficient copy and have a mixed population of red cells — some normal, some not — with an enzyme level that tests as normal or borderline. Where ancestry or family history raises the question, we say so rather than treating a single normal number as the end of it.
We ask about the history that points to it: an episode of jaundice or dark urine after an infection, a drug, or a plate of fava beans; a family member with "a blood problem" in childhood; a newborn screening result. Any of those moves the test from routine to essential.
Other oxidative stressors are noted. Some antimalarials, some antibiotics and high-dose vitamin C are on the same list. The antidepressant page covers the other interaction that rules methylene blue out.
Frequently asked questions
An inherited shortage of an enzyme that protects red blood cells from oxidative damage. Under stress from certain drugs, infections or foods, the cells break apart. It is the most common human enzyme deficiency and most carriers do not know.
Methylene blue is an oxidizing agent. In G6PD-deficient red cells it triggers hemolysis — the cells rupture — which can cause severe anemia and kidney injury. It is a labeled contraindication.
Yes. We draw it with the baseline panel and will not prescribe without a result.
Yes. Most carriers have never encountered a sufficient oxidative stress. Absence of a past episode is not evidence of a normal enzyme.
Men more than women, and people with ancestry from Africa, the Mediterranean, the Middle East, and South and Southeast Asia. It occurs in every population.
Sudden fatigue, breathlessness, pale or yellowed skin, yellowed eyes, dark or red-brown urine, back or abdominal pain. It is a medical emergency.
Where this fits in your plan
The Methylene Blue page covers the drug and its evidence. The G6PD assay is part of the baseline panel for anyone considering it.
We measure first. Then we act.
References
- Provayblue (methylene blue injection) prescribing information — Section 4, Contraindications: G6PD deficiency; Section 5, Warnings: hemolytic anemia.
- Nkhoma ET et al. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells, Molecules and Diseases 2009;42:267–278.
- Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Blood 2020;136:1225–1240.
- Rosen PJ et al. Failure of methylene blue treatment in toxic methemoglobinemia: association with glucose-6-phosphate dehydrogenase deficiency. Annals of Internal Medicine 1971;75:83–86.
- Youngster I et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Safety 2010;33:713–726.
- Back toMethylene Blue
- Methylene blue and antidepressantsMethylene blue is an MAO inhibitor. With an SSRI, SNRI or several other drugs it can cause serotonin syndrome. Why this is a flat no, what the FDA said, and what to disclose.Read
- Methylene blue and memoryOne small fMRI study, a bipolar-depression crossover, and a decade of Alzheimer's trials of a modified form. What the human evidence for methylene blue and cognition actually is, and why "nootropic" is a stretch from it.Read
- Comprehensive lab panelA comprehensive blood panel establishing your baseline across key health markers.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.
Dark urine, jaundice or sudden breathlessness after taking methylene blue needs emergency care.